Item 2.02 Results of Operations and Financial Condition.

Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2020, Intellia Therapeutics, Inc. (the "Company") announced on January 7, 2021, that it expects to report that it had approximately $597 million of cash, cash equivalents and marketable securities as of December 31, 2020.

The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2020. The audit of the Company's consolidated financial statements for the year ended December 31, 2020 is ongoing and could result in changes to the information set forth above.

The information in this Item 2.02 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On January 7, 2021, the Company issued a press release titled "Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021." A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
Number    Description

99.1        Press release dated January 7, 2021  .
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)



                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses